title: Rivaroxaban for the Long-term Treatment of Spontaneous Ovarian Vein Thrombosis Caused by Factor V Leiden Homozygosity.
abstract: OBJECTIVE
  To report a case where rivaroxaban was used in the management of an ovarian vein thrombosis and to briefly review the literature, pathophysiology, and clinical implications therein.
  
  
  METHODS
  A 30-year-old previously healthy woman was diagnosed with acute, spontaneous, left-ovarian vein thrombosis (OVT) with proximal extension into the renal vein. After initial catheter-directed thrombolysis with tPA, angioplasty of the left renal vein, and heparinoid treatment, rivaroxaban was begun for long-term anticoagulation. Three months after her index event she was symptom free, with complete resolution of her thrombosis and no adverse effects or bleeding complications from rivaroxaban. To our knowledge, this is the first report of OVT successfully treated with rivaroxaban.
  
  
  CONCLUSIONS
  OVT is a rare but potentially fatal cause of abdominal pain that may pose diagnostic and therapeutic dilemmas. Factor V Leiden (FVL) homozygosity, an uncommon but severe inherited thrombophilia, increases the risk of thrombosis by approximately 50- to 80-fold. This case report and accompanying literature review highlight important clinical pearls related to the diagnosis and management of OVT and inherited thrombophilias.
  
  
  CONCLUSIONS
  This clinical vignette adds to the published literature suggesting that novel oral anticoagulants, such as rivaroxaban, may eventually emerge as an alternative to vitamin K antagonists for the treatment of extra-axial thromboses. Reporting these cases is important because their prevalence is low outside of specialized referral centers, and thus, dissemination of these experiences may help other providers in treating their patients.
authors.affiliation: University of Utah Health Sciences Center, Salt Lake City, UT, USA.
authors.forename: Rhett M
authors.initials: RM
authors.lastname: Cook
authors.affiliation: University of Utah Health Sciences Center, Salt Lake City, UT, USA.
authors.forename: Matthew T
authors.initials: MT
authors.lastname: Rondina
authors.affiliation: University of Utah Health Sciences Center, Salt Lake City, UT, USA devin.horton@hsc.utah.edu.
authors.forename: Devin J
authors.initials: DJ
authors.lastname: Horton
keywords: anticoagulation; factor V Leiden; ovarian vein thrombosis; rivaroxaban; thrombophilia